热门资讯> 正文

Sangamo Therapeutics申请第11章破产

2026-06-23 18:06

Sangamo Therapeutics, Inc.(SGMO) 0
瑞杰金融(RJF) 0

Biotech firm Sangamo Therapeutics (SGMO) is said to have filed for Chapter 11 bankruptcy protection in Delaware on Tuesday, reporting both assets and liabilities estimated between $100M and $500M as it seeks to navigate its worsening financial constraints.
The company had recently retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its promising pipeline and to maximize value for all stakeholders.

More on Sangamo Therapeutics

Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow
Sangamo Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June
Sangamo Therapeutics Q1 2026 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。